netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Fate found 17 matches

Formulary items 11 matches
   
Open monograph to display formulary status BNF Category
  Atazanavir sulFate and cobicistat Infections - Protease inhibitors - 05.03.01
  Barium sulFate  E-Z-HD® Preparations for Use in Radiology - Enteral Nutrition - 17
  Barium sulFate  Polibar® Preparations for Use in Radiology - Enteral Nutrition - 17
  Chondroitin sulFate  (Gepan Instill®)
(Bladder Installation) 		Obstetrics, Gynaecology, and urinary-tract disorders - Bladder instillations and urological surgery - 07.04.04
  Quinine sulFate Musculoskeletal and joint diseases - Nocturnal leg cramps - 10.02.02
  Sodium PicosulFate
(Elixir) 		Gastro-intestinal system - Stimulant laxatives - 01.06.02
  Sodium PicosulFate with Magnesium Citrate  (Citrafleet® Picolax®) Gastro-intestinal system - Bowel cleansing preparations - 01.06.05
  Sodium thiosulFate (anhydrous)  (Pedmarqsi®) Malignant disease and immunosuppression - Drugs for cytotoxic-induced side-effects - 08.01
  Restricted Drug SucralFate 1g/5ml oral suspension Gastro-intestinal system - Chelates and complexes - 01.03.03
  SucralFate 2g/50ml enema Gastro-intestinal system - Local preparations for anal and rectal disorders - 01.07
  SucralFate cream Skin - Barrier preparations - 13.02.02
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in subsection MHRA Drug Safety Update (Aug 2020): Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available over-the-counter: new measures to support safe use (01.06.02)
link in drug section MHRA Drug Safety Update (May 2019): Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy (02.03)
link in drug section MHRA Drug Safety Update (May 2019): Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy (03.01)
link in drug section MHRA Drug Safety Update (Sept 2019): Elmiron (pentosan polysulfate sodium): rare risk of pigmentary maculopathy (07.04.03)
link in drug section NICE TA1034: Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours (08.01)
link in drug section NICE TA610: Pentosan polysulfate sodium for treating bladder pain syndrome (07.04.03)


 
netFormulary